Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 31 - Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications

  • Daniel Gibbs, Emeritus of Oregon Health and Science University
  • Book:
    Dispatches from the Land of Alzheimer's
    Published online:
    19 January 2024
    Print publication:
    22 February 2024, pp 127-129

  • Summary

    Evidence of beta-amyloid plaques can be found in the brains of people up to 20 years prior to the onset of cognitive impairment due to Alzheimer’s disease and yet, some people with beta-amyloid plaques will never develop Alzheimer’s. Abnormal tau protein starts to appear in neurofibrillary tangles in the brain later but still at least several years before the onset of cognitive impairment. Information from amyloid and tau PET scans as well as new blood tests for beta-amyloid and tau have confirmed this timeline. A recent paper shows how it might be possible to identify research subjects who are in this narrow window, those who currently have amyloid but no tau, but who have characteristics suggesting that they will become tau-positive and cognitively impaired within five years.